GRAL logo

GRAL GRAIL Inc.

NASDAQ · Medical - Diagnostics & Research · Healthcare

$100.98
-3.86 (-3.68%)

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides devel…

Market Cap: $4.54Bwww.grail.com

Price

No data yet.

Social Signal Score

50
5d
48
4 mentions
—
30d
52
13 mentions
—
60d
52
26 mentions
—
90d
49
33 mentions
—
news: 26 · rss: 7

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 5Hold 4Sell 0Strong Sell 0
Avg price target$115.29+14.2%
Low $60Median $118High $175
Current Consensus

Revenue

$37.53M+91.09%
$19.64M$27.99M$36.34M$44.69M
Apr 2023Sep 2026

Analyst Estimates

FY2025
$-11.41
$-13.27–$-10.46
2 analysts
FY2026
$-9.58
$-9.61–$-9.55
4 analysts
FY2027
$-9.85
$-10.41–$-9.27
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Joshua J. Ofman
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
910
Beta
3.25
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
4.54
www.grail.com